Although limited by a small cohort size our analysis suggests that DNA-BD BRCA2mut may predict increased sensitivity to PARPi. Legal entity responsible for the study Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

almost 2 years ago

Clinical • BRCA Biomarker • PARP Biomarker • Metastases

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)

BRCA2 mutation • BRCA1 mutation • BRCA mutation • BRCA2 rearrangement

over2years

large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients (AACR-NCI-EORTC 2022)

The detection of more BRCA1/2 mutations in patients of ovarian cancer is important for efforts to provide targeted therapy. No

over 2 years ago

Clinical • BRCA Biomarker • PARP Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)

BRCA2 mutation • BRCA1 mutation • BRCA mutation • BRCA2 rearrangement • BRCA1 negative • BRCA1 rearrangement

over2years

Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells. (PubMed, Mol Cell)

Importantly, the MiDAS sites identified in BRCA2-deficient cells also represent hotspots for genomic rearrangements in BRCA2-mutated breast tumors. Thus, our work provides a mechanism for how tumor-predisposing BRCA2 inactivation links transcription-induced DNA damage with mitotic DNA repair to fuel the genomic instability characteristic of cancer cells.

over 2 years ago

Journal • BRCA Biomarker

BRCA2 (Breast cancer 2, early onset)

BRCA2 mutation • BRCA2 rearrangement